A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

• Number of Participants With Any Adverse Event (AE): Interim Analysis [ Time Frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264) ] [ Designated as safety issue: No ]
  An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the "Other (Non-Serious) Adverse Events" section.
  
  
• Number of Participants With Any Adverse Event (AE): Final Analysis [ Time Frame: Post January 2006; for up to 241 weeks ] [ Designated as safety issue: No ]
  An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the "Other (Non-Serious) Adverse Events" section.
  
  
• Change From Baseline in the Indicated Clinical Chemistry Parameters at Weeks 48, 96, 120, 132, 168, 180, 204, and 216 [ Time Frame: Baseline (Day 1) and Weeks 48, 96, 120, 132, 168, 180, 204, and 216 ] [ Designated as safety issue: No ]
  Fasting blood samples of participants were collected for the assessment of triglycerides (Tri.), cholesterol (Chol.), high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG). Change from Baseline at Weeks (W) 48, 96, 120, 132, 168, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).
  
  
• Median Values of the Indicated Clinical Chemistry Parameters at Weeks 120, 180, 204, 216, and 432 [ Time Frame: Weeks 120, 180, 204, 216, and 432 ] [ Designated as safety issue: No ]
  Fasting blood samples of participants were collected for the assessment of triglycerides, cholesterol, high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG).
  
  
• Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 120, 180, 204, and 216 [ Time Frame: Baseline (Day 1) and Weeks 48, 120, 180, 204, and 216 ] [ Designated as safety issue: No ]
  blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).
  
  
• Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 96, 132, and 168 [ Time Frame: Baseline (Day 1) and Weeks 48, 96, 132, and 168 ] [ Designated as safety issue: No ]
  Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).
  
  
• Median Value of the Total Cholesterol/HDL Ratio at Weeks 120, 180, 204, 216, and 432 [ Time Frame: Weeks 120, 180, 204, 216, and 432 ] [ Designated as safety issue: No ]
  Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL.
  
  
• Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 120, 180, 204, and 216 [ Time Frame: Baseline (Day 1) and Weeks 48, 120, 180, 204, and 216 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).
  
  
• Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 96, 132, and 168 [ Time Frame: Baseline (Day 1) and Weeks 48, 96, 132, and 168 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).
  
  
• Median Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase Values at Weeks 120, 180, 204, 216, and 432 [ Time Frame: Weeks 120, 180, 204, 216, and 432 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase.
  
  

• Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <400 and <50 Copies Per Milliliter at Baseline and Weeks 48, 120, 180, and 216 (MD=F and Observed) [ Time Frame: Baseline and Weeks 48, 120, 180, and 216 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.
  
  
• Percentage of Participants With Plasma HIV-1RNA <400 and <50 Copies Per Milliliter at Baseline and Weeks 12, 24, 48, 60, 96, and 132 (MD=F and Observed) [ Time Frame: Baseline and Weeks 12, 24, 48, 60, 96, and 132 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point.
  
  
• Percentage of Participants With Plasma HIV-1RNA <50 Copies Per Milliliter at Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432 (Observed) [ Time Frame: Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma,is an efficacy measure for antiretroviral drugs.
  
  
• Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 48, 120, 168, 180, 204, and 216: Observed Analysis [ Time Frame: Baseline and Weeks 48, 120, 168, 180, 204, and 216 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.
  
  
• Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 24, 48, 96, 132, and 168: Observed Analysis [ Time Frame: Baseline and Weeks 24, 48, 96, 132, and 168 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.
  
  
• Median Plasma HIV-1 RNA at Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216 [ Time Frame: Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.
  
  
• Median Plasma HIV-1 RNA at Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168 [ Time Frame: Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.
  
  
• Median Plasma HIV-1 RNA at Weeks 180, 240, 300, 360, 420, and 432 [ Time Frame: Weeks 180, 240, 300, 360, 420, and 432 ] [ Designated as safety issue: No ]
  Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.
  
  
• Number of Participants With HIV-1 Disease Progression to CDC Class C, or New CDC Class C or Death, From Baseline [ Time Frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264) ] [ Designated as safety issue: No ]
  The number of participants with progression of HIV-1 disease were assessed using the CDC classification of HIV-1: class A, asymptomatic or lymphadenopathy; class B: symptomatic, but not AIDS; class C, AIDS. A participant is considered to have had a disease progression if they report a CDC Class C event for the first time, if they report a new CDC Class C event, or if they experience any fatal adverse event during the study.
  
  
• Number of Participants Enrolled in Studies APV30001 and APV300002 With the Indicated HIV-associated Conditions [ Time Frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264) ] [ Designated as safety issue: No ]
  The number of participants with the indicated HIV-associated conditions were assessed, excluding recurrences.
  
  
• Number of Participants Enrolled in Study APV30003 and Other Studies With the Indicated HIV-associated Conditions [ Time Frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264) ] [ Designated as safety issue: No ]
  The number of participants with the indicated HIV-associated conditions were assessed.
  
  

Drug: fosamprenavir (GW433908) Drug: ritonavir
Other Names:
• fosamprenavir (GW433908)
• ritonavir

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.